Search Within

Brenda Y Hurtado

  1. "Center for Molecular Imaging and Biotechnology"
Formats
  1. Meeting Abstract (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  2. Center for Molecular Imaging and Biotechnology (1)
  3. Department of Medicine (1)
  4. Department of Pathology and Laboratory Medicine (1)
  5. GSK Faculty (1)
  6. Solid Tumor Oncology Division (1)

More Groups

People
  1. Charles Rudin (1)
  2. Kaitlin Woo (1)
  3. Lee Krug (1)
  4. Maria Pietanza (1)
  5. Mark Kris (1)
  6. Martin Fleisher (1)

More People

Years
  1. 2016 (1)
Publications
  1. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Clinical Oncology (1)

Results (1)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs)
    Meeting Abstract

    Pietanza, M. C.; Krug, L. M.; Waqar, S. N.; Dowlati, A.; Hann, C. L.; Chiappori, A.; Owonikoko, T. K.; Woo, K.; Bensman, Y.; Hurtado, B.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save